- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Quality of Life Impacted By CLL and SLL Diagnosis and Management
Clinical manifestations and impact on patient quality of life amid diagnosis and management of CLL and SLL are discussed.
EP: 1.Clinical Characteristics Distinguishing CLL and SLL
EP: 2.Quality of Life Impacted By CLL and SLL Diagnosis and Management
EP: 3.Evaluating Current Treatment Landscape of CLL and SLL
EP: 4.Unmet Needs In CLL and SLL Treatment Management
EP: 5.Indications and Considerations For BTK Inhibitor Use In CLL and SLL Management
EP: 6.Examining Safety and Efficacy of BTK Inhibitors In CLL and SLL Treatment
EP: 7.Determining Optimal CLL / SLL Therapy: Ibrutinib, Acalabrutinib and Zanubrutinib
EP: 8.Key Highlights From ASH 2023
EP: 9.Economic Burden Associated With BTK Inhibitor Use
EP: 10.Patient Education Driving BTK Inhibitor Treatment Adherence
EP: 11.Optimizing BTKi Treatment Strategies
EP: 12.Key Considerations for Treating Patients Diagnosed With CLL and SLL
This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA; Tara Graff, DO, MS; Ryan Jacobs, MD; Deborah Stephens, DO; and Jennifer Woyach, MD.
In this video, Graff provides an overview of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), noting that they are forms of non-Hodgkin lymphoma despite the term “leukemia” being used. She explains that while CLL involves malignant lymphocytes floating in the blood and SLL involves malignant lymphocytes in the lymph nodes, many patients have a hybrid of both diseases.
Jacobs then discusses the incidence and prevalence of CLL and SLL. He states that the incidence, or number of new cases per year, of CLL is about 1% of cancer diagnoses annually in the US, and he has not seen data showing this changing over time. However, the prevalence, or number of people living with CLL, is increasing for a few reasons—the aging population, since the average age of diagnosis is around 70 years old, as well as improved treatments helping patients live longer. He notes estimates that CLL prevalence will increase by about 50% from 2015 to 2025.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More
